To the Australian Therapeutic Goods Administration and the Australian Minister for Health Tanya Plibersek,
The Australian Therapeutic Goods Administration has refused to register Human Genome Sciences and GlaxoSmithKline's Benlysta® for use in Australia.
Benlysta® is the first medication developed specifically to treat patients with lupus. Unless it is registered doctors and patients will not have access to all the available treatment options.